Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Clinical Trial Results
Biotech
Immunic MS asset misses primary goal of midstage trial
IMU-838 showed only “modest benefit” over placebo at improving the yearly rate of percent brain volume change in patients with progressive MS.
Darren Incorvaia
Apr 30, 2025 3:05pm
Fecal transplants alleviate fibromyalgia pain in small trial
Apr 28, 2025 7:30am
ALX Oncology doubles down as lead asset fails 2 phase 2 trials
Apr 25, 2025 2:25pm
Large trial reveals link between lowered BP and dementia risk
Apr 24, 2025 11:33am
Avidity's latest DMD data drop assuages safety concerns: analyst
Mar 17, 2025 2:00pm
Emalex eyes potential Tourette approval after phase 3 win
Feb 25, 2025 1:18pm
